EmeraMed Ltd.

DUBLIN, July 14, 2023 /PRNewswire/ -- The "Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering. With an extensive focus on 65+ companies and 70+ pipeline drugs, this report provides a detailed analysis of the current scenario and growth prospects across the indication. The report encompasses a comprehensive overview of the pipeline drug profiles, covering both clinical and nonclinical stage products. Additionally, it includes a thorough assessment of therapeutics, considering product type, stage, route of administration, and molecule type. Inactive pipeline products in this space are also highlighted, providing a holistic view of the COPD pipeline landscape. To provide a comprehensive understanding, this report outlines the present scenario and growth prospects in the COPD field. It offers detailed insights into the disease overview and treatment guidelines for Chronic Obstructive Pulmonary Disease, setting the stage for a deeper exploration of the pipeline landscape. Furthermore, the report delves into the commercial assessment and clinical assessment of the pipeline products under development. It provides detailed descriptions of each drug, including their mechanisms of action, clinical studies, NDA approvals (if any), and comprehensive product development activities. This encompasses technology, COPD collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant product-related details. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Disease Emerging Drugs Chapters This segment of the Chronic Obstructive Pulmonary Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Chronic Obstructive Pulmonary Disease Emerging Drugs Benralizumab: AstraZeneca Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin-5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking, signal transduction. Dupilumab: Sanofi Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL) that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reactions, and rhinosinusitis. Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Dupilumab is under investigation for its potential therapeutic use in chronic obstructive pulmonary disease and is currently in the Phase III stage of development. Tezepelumab: Amgen Tezepelumab (Tezspire) is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. Specifically, TEZSPIRE targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic, and other types of airway inflammation associated with severe asthma. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses, and other airborne particles. Expression of TSLP is increased in the airways of patients with asthma and has been correlated with disease severity. Blocking TSLP may prevent the release of pro-inflammatory cytokines by immune cells, resulting in the prevention of asthma exacerbations and improved asthma control. Tezspire is being developed in collaboration with AstraZeneca and is currently being evaluated in Phase II to treat patients with chronic obstructive pulmonary disease. SNG001: Synairgen SNG001 boosts antiviral responses in the lungs, has a beneficial effect on lung function, and in more difficult to treat patients, improves asthma control during cold infections. The drug is currently being evaluated in the Phase II stage of development to treat patients with COPD. GSK3923868: GlaxoSmithKline GSK3923868, is a PI4kb inhibitor in development as a treatment for viral COPD exacerbations. It belongs to the class of antiasthmatics. The drug acts as a 1-phosphatidylinositol-4-kinase inhibitor. Currently, the drug is in Phase I of its clinical trial evaluation for the treatment of chronic obstructive pulmonary disease. Chronic Obstructive Pulmonary Disease: Therapeutic Assessment This segment of the report provides insights about the different Chronic Obstructive Pulmonary Disease drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Chronic Obstructive Pulmonary Disease There are approx. 65+ key companies which are developing the therapies for Chronic Obstructive Pulmonary Disease. The companies which have their Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca. Phases Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Intramuscular Molecule Type Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Product Type Chronic Obstructive Pulmonary Disease Report Insights Chronic Obstructive Pulmonary Disease Pipeline Analysis Therapeutic Assessment Unmet Needs Impact of Drugs Key Players Sanofi AstraZeneca Amgen Synairgen GlaxoSmithKline Eisai Meridigen Biotech Chiesi EmeraMed Limited Verona Pharma Tetherex Pharmaceuticals Mereo BioPharma Key Products Lemborexant UMC119-06 CHF5259 Emeramide Ensifentrine SNG001 GSK3923868 Benralizumab Dupilumab Tezepelumab SelK2 BCT197 For more information about this clinical trials report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Los Angeles, USA, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Multiple System Atrophy Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade Multiple System Atrophy Clinical Trial Analysis and Therapeutic Assessment of 20+ Companies and MSA Drugs DelveInsight’s “ Multiple System Atrophy (MSA) Pipeline Analysis, 2020 ” highlights the details of the Multiple System Atrophy Pipeline Landscape Scenario, including disease overview, unmet needs, and Multiple System Atrophy therapeutic assessment of the key Multiple System Atrophy pipeline therapies. Some of the key features of the Multiple System Atrophy Pipeline Report 20+ key companies are working to strengthen the Multiple System Atrophy pipeline including the MODAG GmbH , Biogen, GE Healthcare and several others. key companies are working to strengthen the Multiple System Atrophy pipeline including the and several others. Multiple System Atrophy market presents promising and a vast new product pipeline with pivotal trials, NME Projects and phase-advancing therapeutic candidates. 25+ Pipeline therapies in different states of clinical development. Pipeline drugs profiled in the report include: BIIB101, verdiperstat (AZD3241), AAV2-GDNF gene therapy , etc. Pipeline therapies in different states of clinical development. Pipeline drugs profiled in the report include: , etc. Collaborations and Deals Multiple System Atrophy Pipeline Drug Profiles provided include: Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others. Multiple System Atrophy Pipeline Drugs Phases of development Mechanism of Action Route of Administration Companies involved including originator, licensing companies, developer, investors, and others New molecular entity details Multiple System Atrophy Drug designations and other special status provided by regulatory authorities Multiple System Atrophy Market Drivers and Barriers Multiple System Atrophy is a rare, degenerative neurological disorder affecting the body's involuntary (autonomic) functions, including blood pressure, breathing, bladder function, and motor control. The Multiple System Atrophy cause is unknown. The vast majority of cases are sporadic. Request Multiple System Atrophy Therapeutics Pipeline Assessment Sample Report Prominent companies participating in the Multiple System Atrophy therapeutic development are covered in the pipeline report. Multiple System Atrophy Pipeline Therapeutics Verdiperstat by Biohaven Pharmaceutical Holding Company Verdiperstat is a potential first-in-class, oral, brain-penetrant, irreversible inhibitor of MPO that Biohaven Pharmaceutical Holding Company is developing for Multiple System Atrophy treatment. Verdiperstat also has the potential to be developed in a number of other disease indications associated with oxidative stress, inflammation, and neurodegeneration. Verdiperstat has also been known as BHV-3241 at Biohaven. The drug is currently in the phase III stage of development. To know more about Multiple System Atrophy Drugs, request @ Multiple System Atrophy Therapeutics Pipeline Assessment Sample Report Scope of Multiple System Atrophy Pipeline Therapeutics Report Coverage: Global Global Major Players: 20+ Key Multiple System Atrophy Companies Multiple System Atrophy Prominent Players: Brain Neurotherapy Bio, Inc., Biogen, Zambon SpA, EmeraMed, GE Healthcare, Biohaven Pharmaceuticals, Inc., H. Lundbeck A/S, MODAG GmbH, Theravance Biopharma, Voyager Therapeutics Inc, United Neuroscience Ltd, Stealth BioTherapeutics, ProMIS Neurosciences Inc, Newron Pharmaceuticals SpA, Neuropore Therapies Inc, Inhibikase Therapeutics Inc, ICB International Inc, Alterity Therapeutics Ltd, and many others. Brain Neurotherapy Bio, Inc., Biogen, Zambon SpA, EmeraMed, GE Healthcare, Biohaven Pharmaceuticals, Inc., H. Lundbeck A/S, MODAG GmbH, Theravance Biopharma, Voyager Therapeutics Inc, United Neuroscience Ltd, Stealth BioTherapeutics, ProMIS Neurosciences Inc, Newron Pharmaceuticals SpA, Neuropore Therapies Inc, Inhibikase Therapeutics Inc, ICB International Inc, Alterity Therapeutics Ltd, and many others. Key Drugs: 30 Drugs Multiple System Atrophy Pipeline Therapies : Verdiperstat, AAV2-GDNF gene therapy, BIIB101, Safinamide Methanesulfonate, DaTSCAN™ Ioflupane (123I) Injection, [F-18]PBR06, Droxidopa, anle138b, ampreloxetine, VY-SMN101, UB 312, SBT 272, TDP-43 protein inhibitors, Safinamide, NPT 200 11, Alpha-synuclein SMART molecule, ATH 434, EGCG, Rifampicin, Tllsh2910, IVig, Intranasal Insulin, CoQ10, Sirolimus, NBMI, PD01A, PD03A, MSC, PBT-434, Exendin-4, and many others. Verdiperstat, AAV2-GDNF gene therapy, BIIB101, Safinamide Methanesulfonate, DaTSCAN™ Ioflupane (123I) Injection, [F-18]PBR06, Droxidopa, anle138b, ampreloxetine, VY-SMN101, UB 312, SBT 272, TDP-43 protein inhibitors, Safinamide, NPT 200 11, Alpha-synuclein SMART molecule, ATH 434, EGCG, Rifampicin, Tllsh2910, IVig, Intranasal Insulin, CoQ10, Sirolimus, NBMI, PD01A, PD03A, MSC, PBT-434, Exendin-4, and many others. Multiple System Atrophy Drugs Phases: Multiple System Atrophy Therapies Late-stage (Phase III) Multiple System Atrophy Therapies (Phase II) Multiple System Atrophy Therapies (Phase I) Multiple System Atrophy Therapies Pre-clinical stage candidates Inactive candidates Multiple System Atrophy Drug Targets Protease Immune System Multiple Kinase Mechanism of Action Protease Inhibitor Immunomodulatory Multiple Kinase Inhibitor Molecule Types: Small molecule Stem Cell Therapy Gene Therapy Route of Administration: Inhalation Intravenous Oral Subcutaneous Product Types: Mono Combination Key Questions regarding Current Multiple System Atrophy Treatment Landscape and Emerging Therapies Answered in the Pipeline Report What are the current options for Multiple System Atrophy treatment? How many companies are developing therapies for the treatment of Multiple System Atrophy? How many Multiple System Atrophy emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of Multiple System Atrophy? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Multiple System Atrophy market? Which are the dormant and discontinued products and the reasons for the same? What is the unmet need for current therapies for the treatment of Multiple System Atrophy? What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Multiple System Atrophy therapies? What are the key designations that have been granted for the emerging therapies for Multiple System Atrophy? How many patents are granted and pending for the emerging therapies for the treatment of Multiple System Atrophy? Multiple System Atrophy Pipeline Insight Table of Contents Browse Detailed TOC, Emerging Drugs and Key Companies @ Multiple System Atrophy Pipeline Scenario Related Reports DelveInsight’s Multiple System Atrophy (MSA) Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology. DelveInsight's Multiple System Atrophy (MSA) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Multiple System Atrophy (MSA) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. DelveInsight's Postmenopausal Vaginal Atrophy - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. Postmenopausal Vaginal Atrophy Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Postmenopausal Vaginal Atrophy market. DelveInsight's Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology. DelveInsight's Septic Shock Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology. DelveInsight's Geographic Atrophy (GA) Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Contact Us: Shruti Thakur info@delveinsight.com +1(919)321-6187